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ABSTRACT Neuronal degeneration is one of the hall-
marks of Alzheimer disease (AD). Given the paucity of molec-
ular markers available for the identification of neuronal
subtypes, the specificity of neuronal loss within the cerebral
cortex has been difficult to evaluate. With a panel of four
monoclonal antibodies (mAbs) applied to central nervous
system tissues from AD patients, we have immunocytochemi-
cally identified a population of vulnerable cortical neurons; a
subpopulation of pyramidal neurons is recognized by mAbs
3F12 and 44.1 in the hippocampus and neocortex, and clusters
of multipolar neurons in the entorhinal cortex reactive with
mAb 44.1 show selective degeneration. Closely adjacent stel-
late-like neurons in these regions, identified by mAb 6A2, show
striking preservation in AD. The neurons recognized by mAbs
3F12 and 44.1, to the best of our knowledge, do not comprise
a single known neurotransmitter system. mAb 3A4 identifies a
phosphorylated antigen that is undetectable in normal brain
but accumulates early in the course of AD in somas of
vulnerable neurons. Antigen 3A4 is distinct from material
reactive with thioflavin S or antibody generated against paired
helical filaments. Initially, antigen 3A4 is localized to neurons
in the entorhinal cortex and subiculum, later in the association
neocortex, and, ultimately in cases oflong duration, in primary
sensory cortical regions. mAb 3F12 recognizes multiple bands
on immunoblots of homogenates of normal and AD cortical
tissues, whereas mAb 3A4 does not bind to immunoblots
containing neuroframent proteins or brain homogenates from
AD patients. Ultrastructurally, antigen 3A4 is localized to
paired-helical filaments. Using these mAbs, further molecular
characterization of the affected cortical neurons is now possi-
ble.
Alzheimer disease (AD) is a dementing degenerative disease
of the central nervous system (CNS) of unknown cause.
Neuronal loss, neurofibrillary tangles, neuritic plaques,
amyloid angiopathy, and, less commonly, granulovacuolar
degeneration and Hirano bodies constitute the major histo-
pathology.
Whereas much attention has been focused on the neuro-
fibrillary pathology, neuronal loss has been more difficult to
evaluate. There are relatively few selective histologic or
molecular markers for human neuronal subpopulations, thus
limiting identification of the vulnerable neurons. Enzymes
important in the biosynthesis of neurotransmitters, such as
acetylcholine in the nucleus basalis of Meynert (1) and
norepinephrine in the locus ceruleus (2), have been useful
correlates in the histochemical analyses of subcortical nuclei
in normal and AD tissue. Neuronal loss within the cerebral
cortex also may be highly selective. Neuritic plaques and
neurofibrillary tangles have been quantified according to
their regional distribution and correlated with neuronal loss
within the hippocampus and limbic system and in neocortical
association areas (3). Phosphorylated and nonphosphoryl-
ated neurofilament protein (4, 5), the microtubule-associated
proteins tau (6) and microtubule-associated protein 2 (6), and
ubiquitin (7) have also been shown to accumulate abnormally
in certain tangle-bearing cortical neurons in AD. However,
neurofibrillary tangles and neuritic plaques may also occur in
nondemented, aged patients. Furthermore, we have reported
(8) loss of some retinal ganglion cells and an associated optic
neuropathy in some patients with AD. In these sites, no
neurofibrillary tangles, plaques, or amyloid angiopathy were
detected.
Using immunoperoxidase localization, we have defined (9)
a panel of monoclonal antibodies (mAbs) that bind to distinct
neuronal subpopulations in the normal human CNS. Three
mAbs, 3F12, 44.1, and 6A2, identify hippocampal and neo-
cortical neurons in regions of normal brains that are known
to show histopathology in AD. mAb 3F12 binds to a subgroup
of large pyramidal neurons, mAb 44.1 binds to a larger
population of pyramidal and nonpyramidal neurons, and
mAb 6A2 binds to nonpyramidal, stellate-like neurons. In the
hippocampal formation, some ofthe neuronal subpopulations
identified by our mAbs were anatomically well segregated,
whereas in the neocortex, they were intermixed.
In this study, we have utilized these three mAbs to identify
neurons vulnerable to the degenerative process. We have
examined the distribution of mAb reactivity in CNS tissues
obtained at autopsy from AD patients and from age-matched,
nondemented control individuals and patients with other
neurological diseases. A fourth mAb (mAb 3A4) recognizes
an antigen that is readily detectable in the AD cerebrum but
only rarely seen in age-matched controls. The relationship of
the antigen expression to the duration of the disease is also
examined. Preliminary molecular data on two antigens (an-
tigens 3F12 and 3A4) and the relationship of antigen 3A4 to
normal neurofilament proteins and neurofibrillary tangles in
AD are presented.
MATERIALS AND METHODS
The preparation and specificities of mAbs 3A4, 3F12, 6A2,
and 44.1 have been described (9-11). All four mAbs were of
the IgM class.
Tissue Preparation. CNS tissues were obtained postmor-
tem from seven neurologically normal, control patients (ages
25 to 74, with three subjects whose age was more than 60),
Abbreviations: mAb, monoclonal antibody; CNS, central nervous
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one patient with chronic alcoholic dementia (age 76), three
patients with amyotrophic lateral sclerosis (ages 38, 60, and
70), three patients with Huntington disease (ages 55, 63, and
65), and nine patients with clinical histories of dementia and
histologic diagnoses of AD (12) (ages 72-94). The mean
postmortem interval was 3.5 hr (range of 2 to 6 hr) for AD,
7.5 hr (range of 2 to 12 hr) for normal controls, and 10 hr
(range of 4 to 19 hr) for the neurologically diseased controls.
From all patients, tissue blocks (-1 cm3) were dissected from
the hippocampus (at the level of the lateral geniculate
nucleus), basal ganglia, dorsal root ganglia, and spinal cord.
Neocortical sites included superior frontal cortex (Brod-
mann's area 9), primary visual cortex (area 17), and superior
temporal gyrus (area 22). Tissues were rapidly frozen in
liquid nitrogen-cooled isopentane and stored at -90'C.
Histology. Four- to 8-gm-thick cryostat sections were
processed by the single- or double-labeled immunoper-
oxidase or immunofluorescence technique. Thioflavin S
staining of frozen sections was performed as described by
Morrison et al. (13). Bielschowsky, Congo red, and Nissl
stains were performed according to standard procedures.
Phosphatase digestion of frozen tissue sections or nitrocel-
lulose strips from immunoblots used calf intestinal mucosa
alkaline phosphatase (Sigma) (50 ttg/ml) incubated for 1 hr at
370C.
Immunoelectron Microscopy. Tissue blocks (1 mm3) were
dissected from stratum pyramidalis of formalin-fixed AD
hippocampus, embedded in LR-white resin, thin-sectioned,
and stained on the grid. Sections were incubated in 1%
normal mouse serum to block nonspecific binding, incubated
with undiluted mAb 3A4 hybridoma supernatant overnight at
40C, washed, and then incubated with 10-nm gold-labeled
goat anti-mouse immunoglobulin (Janssen Pharmaceutica,
Beerse, Belgium). Sections were then stained with uranyl
acetate and viewed with a Zeiss EM10 electron microscope
at 60 kV.
Immunoblots. The apparent molecular weights of antigens
recognized by the mAbs were determined after electropho-
resis on 8% NaDodSO4/polyacrylamide gel and electroblot-
ting onto nitrocellulose sheets (14). Immunoreactive bands
were detected by autoradiography after labeling with 125[_
conjugated goat anti-mouse antibody or by the ABC-alkaline
phosphatase procedure (Vector Laboratories, Burlingame,
CA).
RESULTS
Hippocampus: Loss ofNeuronal Subpopulation Identified by
mAbs. Our studies indicate a selective loss of distinct
neuronal subpopulations within the hippocampus and cere-
bral cortex in all nine AD patients. Within the hippocampal
formation (Figs. 1A and 2A) of all normal and non-AD
controls, antigen 3F12 is distributed in the soma, axons, and
dendrites of most pyramidal neurons of CA1, subiculum,
layers 3 and 4 of the entorhinal cortex, and rare neurons in
CA2 to -4. In AD, there is loss ofmAb 3F12-reactive material
within these sites and a visible decrease in the number of
labeled pyramidal neurons compared with adjacent Nissl-
stained sections (Figs. 1 A-D and 2B). In contrast to the
pattern ofmAb 3F12, dentate granule neurons and pyramidal
neurons in CA2 to -4 and in layer 6 of the entorhinal cortex
remain essentially intact in Nissl-stained sections in AD and
all control tissues.
In control tissues, antigen 44.1 is present in the perikaryal
cytoplasm and axons of all cells in the above subregions
(Figs. 1E and 2A), and in AD reactive material is also lost or
decreased in these areas (Figs. 1F and 2B). The antibody also
binds to, in control tissues, neurons of the stratum granu-
losum of the dentate gyrus, CA2 to -4, and neurons in layers
2, 4, and 6 of the entorhinal cortex (Fig. 2A). In AD, layer 2
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FIG. 1. Neuronal subset loss in AD subiculum: Pyramidal neu-
rons of normal controls and AD patients. (A and B) mAb 3F12
(immunoperoxidase, x55). (C and D) Nissi (x150). (E and F) mAb
44.1 (immunoperoxidase, x 150). (G and H) mAb 6A2 (immunoper-
oxidase, x 150). Serial sections of normal controls show cytoplasmic
staining of pyramidal neurons by mAbs 3F12 and 44.1 (A, C, and E).
The arrows indicate the same neuron in each serial section. There is
staining of surface membranes of stellate neurons by mAb 6A2 (G).
Companion serial sections ofAD tissues show loss of most pyramidal
neurons in Nissl-, mAb 3F12-, and mAb 44.1-stained sections (B, D,
and F). An intact neuron is indicated in each section by the arrow.
The stellate population in G and H (nonserial sections) is intact.
cells of the entorhinal cortex show the major loss of mAb
44.1-binding neurons (Fig. 2B). mAb 6A2, which identifies
nonpyramidal cells (stellate interneurons) in the subiculum
and in layers 4 and 6 of entorhinal cortex, shows no loss of
binding in AD or control tissues (Figs. 1 G and H and 2 A and
B).
Neocortex: Neuronal Reactivity with mAbs. Within the
neocortex of all AD patients, material reactive with mAb
3F12 is also markedly reduced or absent, but many neurons
remain identifiable with mAbs 44.1 and 6A2. No neuronal
changes were observed either in the normal or other neuro-
logically diseased controls. The mAb 3F12-reactive neurons
are a subset of those stained with mAb 44.1, but there are also
intermingled neurons reactive only with mAb 44.1. It is,
therefore, more difficult to identify neuron loss in these sites
than in the hippocampal formation. Not all neurons that react
with mAb 3F12 are affected by AD. Antigen 3F12 is present
in a subpopulation of small neurons in the spinal cord anterior
horns, the dorsal root ganglia, and the inner segments of
retinal rod photoreceptor cells in control (9) and AD tissues
(data not shown).
mAb 3A4:Neurotibrillary Tangle-Specific Binding. mAb
3A4-binding pattern within the hippocampal formation cor-
responded to the distribution of the neuronal loss in AD (Figs.
2 B and C and 3F). In some neurons, the antigen appeared as
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FIG. 2. Schematic diagram of mAb immunolocalization of neuronal subsets in hippocampal formation and entorhinal cortex. mAbs 3F12,
44.1, and 6A2 in control brains (A) and AD brains (B) (average duration, 8 years). In C, the distribution of mAb 3A4 reactivity is compared to
thioflavin S staining. SUB, subiculum; ENT, entorhinal cortex. In AD note selective loss of neurons reactive with mAb 3F12; and in cells of
layer 2 of the entorhinal cortex note loss of neurons reactive only with mAb 44.1. In C antigen 3A4 follows the distribution of neuronal loss.
multiple, small, discrete globular cytoplasmic aggregates
(Fig. 3B) and in others as large elongate inclusions (Fig. 3E).
Only scant mAb 3A4 binding was observed in the hippo-
campus of one of four age-matched normal controls. Reac-
tivity was absent in all of the non-AD neurologically diseased
controls, including the sites of primary neuronal degenera-
tion: the caudate nucleus in patients with Huntington disease;
anterior horn cells in spinal cords from amyotrophic lateral
sclerosis patients, and cerebral cortex and hippocampus in
patients with alcoholic dementia.
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FIG. 3. Neurofibrillary tangle reactive material in pyramidal
neurons in the subiculum. Serial sections of AD tissues containing
neurons with neurofibrillary tangles and cytoplasmic globules (ar-
rows) (A and B). (A) Bielschowsky stain (x225). (B) mAb 3A4
(immunoperoxidase) (x225). (C) Normal control tissues show no
staining with mAb 3A4 (x85). Serial sections of AD tissue stained
with thioflavin S (D) and with mAb 3A4 (E) show a cytoplasmic
tangle reactive with both stains (x200). In F a pyramidal neuron in
AD tissue is reactive with mAb 3F12 (long arrow; immunoperoxi-
dase) and contains a tangle reactive with mAb 3A4 (short arrow;
immunofluorescence) (x200). (G) Immunoelectron microscopy of
stratum pyramidal in AD hippocampus reveals PHF within some
pyramidal neurons labeled specifically with mAb 3A4 (immunogold,
10-nm particles). (x64,600.)
To determine the relationship of antigen 3A4 to neurofibril-
lary tangles, thioflavin S- and mAb 3A4-binding patterns
were compared in the same or adjacent sections of AD
hippocampus. The thioflavin S-, Congo red-, and anti-paired
helical filament (PHF) mAb-binding patterns co-localized.
The Bielschowsky reaction detected changes in cells also
recognized with either thioflavin S or mAb 3A4. Some
neurons stained only with mAb 3A4, and others stained
solely with thioflavin S. A third, minor group of neurons had
cytoplasmic material reactive with mAb 3A4 and with
thioflavin S (Fig. 2C). Ultrastructurally, immunogold binding
(Fig. 3G) was localized to PHF in some neurons.
Topography of mAb-Binding Sites and Duration of Disease.
The distribution of antigen 3A4- and thioflavin S-reactive
tangles may be related to the duration of the disease. The
length of the clinical course, dated from the time the patient
first became symptomatic, was determined from a careful
clinical history obtained from the caregiver and further
verified by repeated neuropsychological testing. As seen in
Table 1, antigen 3A4, essentially absent in normal brains,
became predominant in brains from patients with a short
clinical course. Clinical duration of a decade or longer was
accompanied by a decrease or absence of mAb 3A4-binding
material in all hippocampal sites. Age-matched normal and
non-AD neurologically diseased controls failed to show
significant mAb 3A4 binding or mAb 3F12 cell-specific loss
in the hippocampus and other sites affected in AD. Although
we have surveyed only a limited number of patients, our
studies suggest that layer 2 of the entorhinal cortex may be
the earliest and most severely affected area, followed by the
subiculum, CA1 of hippocampus, deeper layers of entorhinal
cortex, association areas of neocortex and, lastly, primary
sensory cortex. In patients 1 and 2, where the patient's
demise occurred 1-3 years after diagnosis, affected neurons
in layer 2 of the entorhinal cortex contained material that
reacted extensively with mAb 3A4 as well as thioflavin S. In
all other cases, layer 2 neurons were filled only with
thioflavin S-reactive material. Conversely, in the case of
longest clinical duration (patient 9), there were abundant
neurons with thioflavin S-reactive material in the hippocam-
pus, and mAb 3A4-reactive material was present in associ-
ation cortex and primary neocortex (area 17). These results
suggest that antigen 3A4 appears in neurons prior to
thioflavin S-reactive material.
Immunoblots: Antigens Identified by mAbs. Antigens iden-
tified by mAbs 3F12 and 3A4 were analyzed on immunoblots
using hippocampal or neocortical homogenates. mAb 3F12
identified a major 49-kDa band and minor bands of60, 45, and
42 kDa in homogenates of normal and AD tissues (Fig. 4,
Medical Sciences: Miller et al.
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Table 1. Neurofibrillary tangles in subiculum of AD patients
with various durations of disease
Age, Duration of Tangles stained, %
Patient yr disease, yr Thio 3A4 Thio/3A4
1 88 1 28 72 12
2 76 3 45 55 22
3 77 4 43 57 21
4 94 5 56 44 32
5 72 6 48 52 22
6 89 8 62 38 16
7 87 10 85 15 6
8 90 11 93 7 4
9 78 16 100 0 0
Tangles identified by mAb 3A4, by thioflavin S, or by both were
correlated with the duration of disease as timed from the onset of
clinical symptoms to the patient's demise. Total tangles are defined
by the sum of tangles reactive with either mAb 3A4 or thioflavin
minus those stained by both. A minimum of 100 tangles per patient
were counted. Single staining by either thioflavin S (Thio) or by mAb
3A4 (immunoperoxidase) or double staining by both methods
(Thio/3A4) was on serial sections. Landmarks common to both
sections (e.g., blood vessels) were chosen at random as reference
points. The superimposition of landmarks on adjacent photomicro-
graphs allowed the number and type of tangles to be counted in
specific neurons. Coefficient ofcorrelation ofantigen 3A4 to duration
of disease: r = -0.96. Note the higher percentage of neurons
containing antigen 3A4 than thioflavin S-reactive material in tissues
of patients dying within 5 years after initial onset of symptoms. With
time, a reduction of mAb 3A4-reactive tangles is seen; by 16 years
there is no mAb 3A4-binding material in the subiculum, and all
tangles stain only with thioflavin S.
Although mAb 3A4 binds to some component of PHF,
molecular characterization of antigen 3A4 has been more
elusive. Whereas mAb 3A4 is nonreactive in the normal human
CNS, it reacts strongly with the normal human retinal photo-
receptor outer segment and with axons in the Drosophila
nervous system but faintly with neuronal nuclei in both species
(9). In all human AD and control tissues and in Drosophila
heads, mAb 3A4 binding was inactivated when the tissue was
treated with alkaline phosphatase. Antigen 3A4 was insoluble in
2.3% (wt/vol) NaDodSO4 but still immunohistochemically
reactive, and immunoblots of tissue homogenates of normal or
AD human brain or Drosophila heads were nonreactive with
mAb 3A4. These findings suggest that mAb 3A4 may be binding
to a phosphorylated, highly insoluble protein. Immunocyto-
chemical tests with antibodies to lamin, a neurofilament-like
nuclear protein, to the microtubule-associated protein tau (17),
and to the Alz-50 antigen (18) did not cross react with the mAb
3A4-positive cytoplasmic material in AD tissues. mAb 3A4
failed to react with purified neurofilament protein from normal
human cerebral cortex or white matter. The purified 200-, 150-,
or 68-kDa triplet proteins did not bind mAb 3A4 in immunoblots
(Fig. 4, lane b) or to dot blots (data not shown) but did bind
mAbs with known specificities for phosphorylated and non-
phosphorylated neurofilament proteins (data not shown). Puri-
fied preparations of bovine tau and bovine and rabbit microtu-
bule proteins did not bind mAb 3A4, whereas anti-tau mAb (17)
and mAb Alz-50 (18) gave similar immunoblot patterns. In
preliminary experiments, incubation ofmAb 3A4 supernatants
with purified tau, neurofilament proteins, or ubiquitin failed to
alter its binding pattern on tissues (data not shown).
lanes b and c). Although the 60-kDa band was somewhat
variable in intensity among homogenates from controls, from
twoAD patients (patients 8 and 9) with clinical disease oflong
duration, loss of mAb 3F12 binding to the 60-kDa band may
be related to the marked decrease of mAb 3F12-reactive
material seen in neurons in immunocytochemically stained
sections. No protein band was sensitive to incubation with
alkaline phosphatase. In contrast to the neurospecificity of
antigen 3A4, antigen 3F12 was immunocytochemically de-
tected in nonneural tissues, including squamous epithelium,
lymph nodes, and the medium of cultured small blood
vessels.
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FIG. 4. Immunoblots of hippocampal homogenates. Unfixed,
frozen hippocampal tissues were homogenized, electrophoresed,
and electroblotted onto nitrocellulose. Blots were immunolabeled
with 125I-labeled goat anti-mouse IgG/IgM mixture (2 ,uCi/,ug; 1 Ci
= 37 GBq), dried, and visualized by autoradiography. Lanes: a,
normal tissue homogenate with no primary mAb; b, mAb 3F12
staining of normal tissue homogenate; c, mAb 3F12 staining of AD
tissue homogenate [note reactive bands of 60 (small-arrow), 49, 45,
and 42 kDa]; d, electrophoretic separation of purified (15, 16)
neurofilament triplet proteins (9 ,g per sample) from gray matter
electrophoresed on 10% gels and stained with Coomassie blue (200,
150, and 70 kDa, arrowheads); e, immunoblot of the same gel stained
with mAb 3A4. No reactive material in any component of a neu-
rofilament preparation was detected. Large arrows indicate molec-
ular weight standards.
DISCUSSION
A subpopulation of pyramidal neurons, identified by mAbs
3F12 and 44.1, within the hippocampal formation and neo-
cortex in normal brains, may show selective histopathology
in AD. These results confirm those of Morrison et al. (19) and
Lewis et al. (20) who identified neuronal loss in cortical
association areas that correspond to the distribution of
neuritic plaques and tangles. They suggested that intrinsic
cortical loss may be the major and primary element in the
pathogenesis of AD. The distribution of neuronal loss de-
tected by our mAbs also complements the quantimetric
analyses of Terry et al. (21) that demonstrated loss of some
neocortical pyramidal cells in the size range of >80 gm in
diameter within layers 3 and 5 of the neocortex. In the aging
brain those studies showed only a reduction of somal size in
that neuronal subpopulation. The hippocampal distribution
of neuronal loss in the subiculum, CA1, and layers 2-4 of the
entorhinal cortex is consistent with that reported by Hyman
et al. (22). The early loss of layer 2 neurons of the entorhinal
cortex, a way-station for corticohippocampal projections,
may be the critical factor in loss of memory function.
The cholinergic system is the best recognized neurotransmit-
ter system to be affected in AD, although not all cholinergic
neuronal cell groups are affected. Intrinsic cortical cholinergic
neurons have been described in the rat brain, but, in contrast to
neurons identified by mAb 3F12, they are nonpyramidal in
shape and are mainly in layers 2 and 3 (23). Glutamate, a likely
candidate for the neurotransmitter of these intrinsic pyramidal
neurons, is also affected in AD. There is a loss of glutamate in
the molecular layer of the dentate gyrus, the site of perforant
pathway terminals (18) and of glutamate uptake in cortical and
hippocampal regions (24).
We postulate that, at the cellular level, there is a temporally
related pattern of immunocytochemically detectable changes
occurring in pyramidal neurons affected by AD (Fig. 5). The
first normally present antigen to disappear or to become
nonreactive is antigen 3F12. Antigen 44.1, also initially
present, later becomes undetectable. Antigen 3A4 may be an
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FIG. 5. Hypothetical scheme of antigen loss and progression of
tangle formation within an AD pyramidal neuron. Stains are as
indicated. +, Reactive; -, nonreactive. Dots are intracytoplasmic
globules; the large masses represent tangles. Dotted line surrounding
ghost tangle indicates that the plasma membrane is no longer visible.
earlier indicator of AD than other markers, including mAbs
prepared with isolated tangles as immunogen. This antigen
becomes detectable prior to loss of cellular reactivity with
mAb 3F12, mAb 44.1, or the thioflavin S stain. With time, the
thioflavin S-reactive material remains and is more abundant
than mAb 3A4-reactive material. After a long clinical course,
mAb 3A4-reactive material may be detectable only in the
neocortex, including primary areas. From these studies, it
cannot be determined if antigen 3A4 is no longer present in
the tissues or is further modified and no longer detectable.
Predictably, young, normal controls showed none of the
AD-specific changes. Because of the paucity of autopsy
tissues available from neurologically evaluated normal, age-
matched controls, it is more difficult to assess histologic
changes, especially within the hippocampal formation, where
some histopathology of AD may be seen in the absence of
dementia. Whether these cases are incipient AD or merely
age-related changes is not clear. Evaluation of other, rarer
dementing disorders such as Pick disease is needed but must
be prospectively planned.
Direct biochemical characterization of antigen 3A4 has not
yet been achieved because of its insolubility under standard
conditions. The mAb appears to recognize a phosphorylated
epitope, since treatment with phosphatase eliminates its
reactivity. Neurofilament proteins, microtubule-associated
protein 2 (25), and tau proteins (26) have been demonstrated
to be abnormally phosphorylated in AD. The absence ofmAb
3A4 binding to neurofilaments isolated from human white or
gray matter after NaDodSO4 treatment does not exclude the
possibility that antigen 3A4 is of neurofilament origin and
becomes incorporated into PHF. Native antigen 3A4 may be
in a modified form possibly linked to a nonprotein portion of
the molecule or present in quantities not detectable under gel
electrophoresis conditions.
Similarly, the neuron-specific protein recognized by mAb
3F12 may be the 60-kDa species noted on immunoblots. Its
lability in our preparations has so far made direct character-
ization difficult. Use of the antibody to screen a cDNA
expression library could lead to further insight into the role
of this protein and its corresponding gene in subset-specific
function. Our observations may be useful in defining cellular
mechanisms, and determining the role of genetically deter-
mined factors in the neurons specifically vulnerable to
degeneration in Alzheimer disease.
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